Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma
Despite advances in standards of care, the prognosis of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains poor. In these patients, 50–74% fail to respond to next line therapy,...